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Abstract
Background: This study aims to evaluate and compare the effect of pre-procedural administration of acetaminophen,
ibuprofen, and meloxicam in reducing pain after separator placement.
Methods: Three hundred twenty-one patients who needed orthodontic treatment and aged above 15 were randomly
assigned to one of the three study groups: group A: 650 mg acetaminophen, group B: 400 mg ibuprofen, and group
C: 7.5 mg meloxicam. All subjects received a single dose of medication 1 h prior to separator placement. Using visual
analog scale, patients recorded their pain perception during rest, fitting posterior teeth together, and chewing at time
intervals of immediately, 2, 6, 24, and 48 h after separator placement.
Results: There was no significant difference between acetaminophen, ibuprofen, and meloxicam in post-separator
placement pain control when administered 1 h before the procedure. In all the groups, at rest, pain level elevated after
separator placement and reached its peak at 24 h and then subsided until 48 h. But during chewing and fitting of the
posterior teeth, some of the groups reached a peak in pain at 48 h. No significant difference was found in pain
experience between males and females.
Conclusions: Meloxicam can be used as an effective analgesic in orthodontic pain control considering it has less
gastric side effects compared to the conventional nonsteroidal anti-inflammatory drugs.
Trial registration: Iranian Registry of Clinical Trials, IRCT2015041821828N1
Keywords: Orthodontic pain; Non-selective NSAIDs; Meloxicam
Background
Pain is an unpleasant sensation caused by some tissue
changes. These tissue changes in orthodontic treatment
are caused by the compression of periodontal ligament
and alteration of blood flow to the tooth, resulting in
releasing chemical mediators like prostaglandins [1, 2].
About 95 % of the patients undergoing orthodontic ther-
apy report varying degrees of pain and discomfort during
some stages of treatment such as separator or arch wire
placement [3, 4]. It has also been reported that pain is the
foremost reason for patient aversion and discontinuing
treatment [5, 6]. It has been claimed that degree of pain
experienced by patient varies based on gender, age, patient
anxiety level, and emotional stress [1, 4, 7, 8].
Despite the concerns stated by the orthodontists and
patients, no standard of care has still been defined to
control pain caused by orthodontic appliances [9, 10].
Several methods have been proposed such as administra-
tion of analgesics, introducing vibratory stimulation,
chewing on a bite wafer, and most recently, the use of
low-level laser therapy [11–22].
Analgesics are the most common treatment modality
used to control the pain associated with orthodontic
treatment [15]. Several studies evaluated the effect of
pre- and postoperative use of various medications
including aspirin, acetaminophen, ibuprofen, piroxicam,
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etc. on the orthodontic-induced pain [11–18, 20, 23].
Acetaminophen is an over-the-counter medication with
antipyretic and analgesic effects via central inhibition of
the third isoform of cyclooxygenase enzyme (COX3),
which is mostly found in the cerebral cortex and heart
[13, 24]. The conventional nonsteroidal anti-inflammatory
drugs (NSAIDs) like ibuprofen, piroxicam, aspirin and
naproxen sodium block the production of prostaglandins
through inhibiting the other isoforms of cyclooxygenase
(COX) enzyme [24].These medications are called non-
selective COX inhibitors, since they block both COX1 and
COX2 isoforms [24]. Inhibition of COX1 is responsible for
the adverse effects of NSAIDs such as gastric ulceration
and bleeding disorders [25]. Many studies have been con-
ducted to evaluate the effects of this family of NSAIDs on
the pain relief during orthodontics treatment [11–18].
Bird et al. reported that there was no difference between
the single preemptive use of acetaminophen and ibupro-
fen in pain control after separator placement whereas
Bradley et al. showed that ibuprofen was more effective
than acetaminophen [13, 14].
Another class of NSAIDs that has been recently intro-
duced is selective COX2 inhibitors (coxibs) like celecoxib,
valdecoxib, and lumiracoxib [26]. They retain the benefits
of anti-inflammatory action with minimum side effects
like gastric irritation and platelet functional alteration, and
also, they have longer dose interval [25–28]. Young et al.
showed that pre- and postoperative use of valdecoxib
compared to placebo can effectively decrease pain after
archwire placement, while Bruno et al. found no signifi-
cant difference in post-separator pain between placebo
and lumiracoxib [29, 30].
Meloxicam is one of most popular relatively selective
COX2 inhibitors used in the treatment of acute and
chronic inflammatory painful disorders like rheumatoid
arthritis, dental pain, and postoperative pain [31–33]. It
is now clear that meloxicam has a lower gastric effect
compared to other NSAIDs [31]. Efficacy of this drug in
controlling post-endodontic pain and pain after third
molar removal and oral surgery has been investigated
previously [27, 32, 33].
Recently, there have been some concerns regarding
the increased risk of cardiovascular and renal events as-
sociated with administration of selective COX2 inhibitors
such as valdecoxib, rofecoxib, and lumiracoxib [9, 30].
COX2 inhibitors decrease the production of vascular
prostaglandin I2 (PGI2) which is a vasodilator and anti-
aggregator mediator [34]. In addition, COX2 inhibitors
do not inhibit thromboxane A2 (TxA2) production, one
of COX1 products from arachidonic acid in platelets
which causes irreversible platelet aggregation, vasocon-
striction, and smooth muscle proliferation [34]. How-
ever, available data and systematic reviews suggest that
meloxicam has more desirable cardiovascular and renal
safety profile than other COX2 inhibitors like celecoxib
and rofecoxib [35].
Considering that only few studies have evaluated the
effect of selective COX inhibitors on orthodontic pain
control and no studies have evaluated the effect of
meloxicam as a relatively selective COX2 inhibitor in
orthodontic pain control and given the adverse effects of
conventional NSAIDs, the authors of this study designed
this double-blinded parallel arm randomized clinical trial
study to compare the effect of preemptive administration
of meloxicam with acetaminophen and ibuprofen on
the experienced pain following orthodontic separator
placement.
Methods
The sample size was determined to be 70 in each group
based on the mean pain scores recorded in the similar
study (acetaminophen (31.6 ± 18.8) and ibuprofen
(22.8 ± 17.7)) at α = 0.05 and power = 80 % [13]. One
hundred seven patients were recruited in this study
to account for the potential patient dropouts during
the course of the study. Three hundred twenty-one
patients who needed fixed orthodontic therapy and
were referred to the Orthodontic Clinic of Dental
School at Shiraz University of Medical Sciences, Iran, were
selected for this prospective double-blind randomized
clinical trial investigation. This study was approved by the
ethical committee of Shiraz University of Medical
Sciences. All participants had the following criteria:
1. Need separator placement to begin orthodontic
treatment in the maxillary arch
2. Aged 15 years or older
3. Were informed and signed the written informed
consent
4. Not currently using antibiotics, analgesics, anti-
inflammatory, anti-coagulative, diuretics, oral anti
diabetics, lithium, cyclosporine, and methotrexate
5. No need for antibiotic prophylaxis
6. No chronic systemic disease or clotting disorders
7. Not reporting contraindication for NSAIDs
8. Not pregnant or nursing
The block randomization method was used with block
length 9, and number of repetition for each group m = 3,
to allocate subjects in each group. This method was used
separately for each sex group to provide groups with
equal numbers of male and female. The patients were
divided to three equal groups which were consisted of
78 women and 29 men: group A (650 mg acetamino-
phen), group B (400 mg ibuprofen) and group C (7.5 mg
meloxicam (7.5 mg; BohringerIngelheim Pharms,
Germany)). In each group, all tablets were covered by
identical gelatin cover, so the investigators, the patients,
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and the statistician were all blind to the treatment
groups. All patients were given only one tablet, 1 h before
separator placement (Alastiks S-2separator modules; lot
number A2508, 3M UnitekMonorvia, Calif ) .The time
and the quadrant in which the separators were placed
were recorded.
A visual analog scale (VAS) was used to determine the
level of pain and discomfort at the following intervals: im-
mediately after separator placement (T0), 2 h post-
treatment (T1), 6 h post-treatment (T2), 24 h post-
treatment (T3), and 48 h after separator placement (T4).
Each patient received a booklet consisted of five series of
VAS. The VAS format was a 10 cm line from 0 indicating
no pain to 10 indicating the worst pain a patient has ever
experienced. Patients were instructed to mark the degree
of the pain with a short vertical line on the VAS during
three oral situations including rest, fitting posterior teeth,
and chewing, and return the questionnaire in the next visit
(a week later). While fitting the posterior teeth, the
patients were instructed to bring the teeth together with a
light force and not to eat anything in the process. For the
chewing function, the subjects were instructed to chew on
a slice of granny smith apple and mark the level of the
subsequent pain on the VAS. The patients were asked to
not use other analgesics during the period of the study,
and in case they did so, they would be excluded from the
investigation. Before this study, a pilot study was carried
out with 20 patients who needed to have separators placed
prior to orthodontic treatment. The patients did not take
any medications before the treatment. They were asked to
record their pain score according to the instructions, and
their functions were evaluated via the questionnaire. This
pilot study was just performed to ensure the ease of com-
prehending the instructions by the participants, and none
of the subjects were included in the main study.
Statistical analysis
Statistical analysis was done using the Statistical Package
for Social Sciences (Version 15.0, SPSS Inc., Chicago,
Illinois, USA). Descriptive analysis was performed for pain
scores in three treatment groups for all different time
intervals, at rest, fitting the posterior teeth, and chew-
ing. The normal distribution of the data was tested
with Kolmogorov Smirnov normality test, before applica-
tion of parametric tests. Differences in the mean pain score
between experimental groups were evaluated by analysis of
variance (ANOVA) and Tukey test. Repeated measure
ANOVA and paired t test was conducted to determine the
difference in the pain scores at each time interval. The level
of significance for all tests in our study was set at p < 0.05.
Results
Eighty patients (25 %) were dropped out of the study, of
whom 18 patients used other analgesics during the time
of study, 46 patients did not complete the questionnaires
correctly, and 16 did not return the questionnaires. The
final sample consisted of 60 men (25 %) and 181 women
(75 %), of whom 57 women and 19 men were in the
acetaminophen group, 55 women and 21 men in the
ibuprofen group, and 68 women and 21 men in the
meloxicam group (Fig. 1). No statistical difference was
found between the three study groups in terms of age;
the mean age of the acetaminophen group was 21.7 ± 3.5
and a mean age of 22.1 ± 3.2 and 21.2 ± 3.8 were
recorded for the ibuprofen and the meloxicam groups,
respectively. Table 1 outlines the descriptive information
and ANOVA results for the three groups.
Although, there was no statistically significant difference
in the pain perception scores between the three treatment
groups (Table 1), patients consistently experienced more
pain on T0 and T1 in the meloxicam group and on T3 and
T4 in the ibuprofen group. Additionally, when considering
the peak pain scores, the highest values were in the
ibuprofen group during the rest, and two masticatory
functions and the lowest ones were seen in the
meloxicam group during rest and fitting posterior
teeth. In the chewing function, the difference between
the mean pain score of the three groups tended to be
significant 48 h after separator placement (P = 0.095).
Tukey test showed the difference was between the ibupro-
fen and the acetaminophen groups (P = 0.091). Although,
in all study groups and at all time intervals, subjects expe-
rienced more pain when chewing compared to at rest and
while fitting posterior teeth, but the difference was not
significant. Our results also showed that gender had
no significant effect on pain perception scores in any
treatment groups and for any time intervals.
Significant differences were found in pain perception
scores at different times (P = 0.001), although the trend
was almost similar in all groups and for all masticatory
functions (Figs. 2, 3, and 4). The changes in pain percep-
tion with the time are presented individually for each
medication.
1. Acetaminophen. Generally, pain increased
immediately following separator placement and
reached a peak at 24 h and then subsided until 48 h.
There was no significant change in the level of pain
perceived at rest over time. The results of the paired
t test showed significant difference between T0 and
T1 (P = 0.025), T1 and T2 (P = 0.005), and T2 and
T3 (P = 0.001) while fitting posterior teeth and
between T0 and T1 (P = 0.031), T1 and T2
(P = 0.003), T2 and T3 (P = 0.001) and T3 and T4
(P = 0.011) in chewing function.
2. Ibuprofen. Subjects experienced significant increase
in the level of pain from 2 h after separator
placement until 24 h at rest (T1–T2 (P = 0.038),
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T2–T3 (P = 0.001)). During the two other
functions, patients experienced increased level of
pain until its peak at 48 h. The paired t test showed
significant increase between T2–T3 (P = 0.001) and
T3–T4 (P = 0.001).
3. Meloxicam. The mean pain score increased
immediately after separator placement and reached
the peak at 24 h at rest. There was a significant
increased only between T1 and T2 (P = 0.001);
however, the difference between T2 and T3 (P = 0.061)
tended to be significant during this function. During
the fitting of posterior teeth, the mean pain score
increased immediately after separator placement
until the peak at 24 h (T0–T1 (P = 0.011), T1–T2
(P = 0.001), T2–T3 (P = 0.002)). In the chewing
function, pain increased immediately after
Fig. 1 CONSORT flow diagram
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Table 1 Descriptive information and ANOVA results of three treatment groups
Function Group T0 T1 T2 T3 T4
Rest Acetaminophen 0.58 ± 0.97 0.78 ± 1.26 1.08 ± 1.50 1.48 ± 1.91 1.20 ± 2.01
Ibuprofen 0.54 ± 1.05 0.69 ± 1.30 0.95 ± 1.66 1.78 ± 2.43 1.71 ± 2.24
Meloxicam 0.66 ± 0.93 0.80 ± 1.16 1.13 ± 1.58 1.42 ± 1.98 1.33 ± 1.84
P valuea 0.739 0.844 0.758 0.532 0.276
Fitting posterior teeth Acetaminophen 0.84 ± 1.24 1.13 ± 1.26 1.65 ± 1.69 2.65 ± 2.68 2.10 ± 2.68
Ibuprofen 0.69 ± 1.10 1.06 ± 1.84 1.48 ± 2.04 2.89 ± 3.00 3.02 ± 2.86
Meloxicam 0.99 ± 1.28 1.27 ± 1.52 1.73 ± 2.06 2.44 ± 2.48 2.35 ± 2.54
P valuea 0.281 0.675 0.694 0.566 0.095
Chewing Acetaminophen 1.01 ± 1.46 1.36 ± 1.56 1.96 ± 1.84 3.08 ± 2.97 2.79 ± 3.17
Ibuprofen 0.98 ± 1.52 1.37 ± 2.15 1.89 ± 2.42 3.63 ± 3.24 3.75 ± 3.29
Meloxicam 1.22 ± 1.65 1.50 ± 1.86 2.01 ± 2.14 3.05 ± 2.81 3.16 ± 3.10
P valuea 0.560 0.871 0.939 0.397 0.177
T0 (immediately after separator placement), T1 (2 h), T2 (6 h), T3 (24 h), T4 (48 h)
aANOVA results
Fig. 2 Comparison of the mean pain scores on VAS among the three study groups over the time in the rest position
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separator was placed until 48 h. Significant
differences were found between T0–T1 (P = 0.024),
T1–T2 (P = 0.001), and T2–T3 (P = 0.002)].
Discussion
In this study, the effect of preemptive administration of
acetaminophen, ibuprofen, and meloxicam in controlling
post-separator pain was evaluated and compared using
visual analog scale (VAS). VAS is generally accepted as a
reliable and valid instrument for measuring acute and
chronic pain, and is more sensitive for measuring positive
responses to treatment compared to verbal descriptors
[14, 36]. Our results indicated that there was no significant
difference among three analgesics when administered 1 h
prior to separator placement. Generally, pain increased
immediately after separators were placed and in most
cases reached a peak at 24 h. This result is in accordance
to what has been reported in most of the previous studies
[9, 11, 12, 21].However, slight increase in pain was ob-
served after 24 h in meloxicam group in chewing function
and in ibuprofen group when fitting posterior teeth.
These results are comparable to those of Law et al.
and Farzanegan et al. for 400 mg ibuprofen [12, 21].
Law et al. showed no alleviation in pain after 24 h
“when fitting front teeth together,” and Farzanegan
reported no reduction in pain levels after 24 h “when
chewing” [12, 21]. It may be attributed to the blood
level of medication not reaching its optimum to
reduce pain efficiently in this interval.
Similar to other studies evaluating orthodontic pain level,
the greatest reported pain occurred on chewing rather than
at fitting posterior teeth or at rest [9, 11, 12, 21, 29]. It is
not surprising because the orthodontic pain is the result of
compression, inflammation, and edema in the periodontal
ligament, and there is greater compression during function
in the periodontal ligament (PDL) [21, 29].
Our results showed no difference between acetamino-
phen and ibuprofen when administered 1 h before the
procedure. These findings are similar to those of Bird et
al. that used single pretreatment dose of ibuprofen
Fig. 3 Comparison of the mean pain scores on VAS among the three study groups over the time when fitting posterior teeth
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(400 mg) and acetaminophen (650 mg) 1 h prior to sep-
arator placement [14]. However, Patel et al. and Bradley
et al. reported that ibuprofen was more effective than
acetaminophen in post-separator pain control [13, 17]. It
may be attributed to the administration of the follow-up
doses of medication in the two latter studies. Patel et al.
administered 400 mg ibuprofen or 650 mg acetamino-
phen 1 h before and 3 and 7 h after separator placement
[17]. Bradley et al. used 400 mg ibuprofen or 1 g acet-
aminophen 1 h before and 6 h post-treatment [13].
Bird et al. observed a decrease in pain 2 to 3 h after
separators were placed in ibuprofen (400 mg) and acet-
aminophen (650 mg) group when used 1 h prior to the
treatment [14]. Although this trend was not found in
our study, but during all the masticatory functions in the
ibuprofen group and at rest in the meloxicam group,
there was no significant increase in the mean pain scores
until 2 h. A possible explanation could be that Bird’s
study was performed on a different age range (9 to
19 years) compared to our study (≥15 years) and thus
might have required lower doses of medication to reach
its optimum efficacy.
Our results showed no significant difference between
preoperative administration of meloxicam and the two
other medications in post-separator placement pain con-
trol. To the best of our knowledge, no other studies have
assessed the effectiveness of meloxicam in orthodontic
pain reduction, so there is no previous report for com-
parison. Young et al. conducted a study on valdecoxib (a
selective COX2 inhibitor) and showed that preemptive
administration of the medication followed by five post-
operative doses could effectively control post archwire
placement pain [29]. It should be noted that valdecoxib
has been removed from US and European markets
because of the increased risk of cardiovascular events
and skin reactions [29]. Bruno et al. showed that a single
preoperative dose of lumiracoxib did not significantly re-
duced post-separator pain [30]. Nekoofar et al. proposed
that there was no significant difference between meloxi-
cam (15 mg), piroxicam (20 mg), and placebo in
Fig. 4 Comparison of the mean pain scores on VAS among the three study groups over the time in chewing function
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reducing postoperative endodontic pain when adminis-
tered after treatment [27]. Aoki et al. reported that
premedication with 10 mg meloxicam could reduce
postsurgical pain in patients after lower third molar
extraction [33]. Calvo et al. reported that pain levels after
lower third molar extraction not requiring osteotomy can
be successfully controlled by a single dose regimen of
7.5 mg meloxicam once daily [32].
This is clearly shown that pain during orthodontic
treatment is related to inflammatory responses in the
PDL [1].Orthodontic forces produce ischemia and
inflammation in compressed areas that lead to the
release of high levels of mediators such as prostaglandin
in the PDL [1, 2]. COX2 is the main isoenzyme in the
production of pro-inflammatory prostaglandin and also
plays an important role in centrally generated hypersen-
sitivity process [28, 33].
Meloxicam is a relatively COX2 inhibitor with more
inhibitory effects on COX2 than COX1. Via this inhibi-
tory effect on COX2, it could be effective in orthodontic
pain control. In addition, as it was already mentioned,
COX1 inhibition is responsible for the adverse gastric
effects of non-selective NSAIDs [25]. It has been shown
that meloxicam doses ≤15 mg decreased the incidence
of gastrointestinal side effects such as perforation, ulcer-
ation, and bleeding than non-selective NSAIDs [37]. As
mentioned before, there has been an increased concern
regarding the risk of cardiovascular thrombotic event
associated with the administration of selective NSAIDs
[9, 30]. However, it seems that meloxicam is relatively
safer compared to other medications of this class of
NSAIDs; specifically in lower doses such as what was
used in the current study (a single 7.5 mg), the risk of
cardiovascular events may be very low [33, 35].
Prostaglandins play an important role in stress-related
bone remodeling [38], and the potential effects of
NSAIDs on the rate of orthodontic tooth movement
have been considered. Acetaminophen, an NSAID from
para-aminophenol family, differs from the majority of
selective and non-selective NSAIDs; it does not inhibit
or slightly inhibits the formation of prostaglandins and
thus does not affect orthodontic tooth movement [39, 40].
It has been shown that meloxicam does not affect ortho-
dontic tooth movement after 2 weeks of administration
via drinking water in Wistar rats and seems to be safer
than other selective NSAIDs [39]. There is no clear
evidence on long-term effects of meloxicam on the rate of
orthodontic tooth movement, and it could be an area of
interest for future studies. In the absence of comprehen-
sive study, it needs to be prescribed with caution.
In contrast to the generally accepted concept that fe-
males have greater perception of pain and lower pain
threshold than males, we found no significant difference
in pain experience between males and females [2, 4].
This finding is similar to several other studies that have
investigated orthodontic pain [16–18, 41].
At the end, it should be noted that the pain is a
subjective sensation which can be influenced signifi-
cantly by factors such as cultural background, previ-
ous traumatic experience, sex, age, and psychological
factors [1, 4, 7, 8, 17, 42]. We expected that the large
sample volume used in the present study could offset
the effects of these variables on our results.
In the present study, we compared the effect of a
single preemptive dose of meloxicam with ibuprofen and
acetaminophen in the control of the separator orthodontic
pain. It can be suggested that a comparison between the
pre- and post-administration of meloxicam and conven-
tional analgesics be carried out in future studies, but the
effect of long-term use of this drug on the rate of ortho-
dontic tooth movement should be noted.
Conclusions
Our findings suggest preoperative administration of
meloxicam (7.5 mg) was as effective as acetaminophen
(650 mg) and ibuprofen (400 mg) to control the post-
separator pain. However, acetaminophen can be consid-
ered as the treatment of choice due to the fact that it
does not cause gastrointestinal (GI) ulcers and does not
affect the rate of tooth movement. Considering the low
GI toxicity, meloxicam can be recommended as a good
alternative for those patients who cannot take other
NSAIDs or acetaminophen.
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